{"name":"Nerviano Medical Sciences (Shanghai) Ltd.","slug":"nerviano-medical-sciences-shanghai-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight - PR Newswire","headline":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technologi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNOXcyek5vakItWXNwTWFOdFM3OEhGZmJieFYxLWl4dDRmNnlaNGN4cXZxM2VyRjMzUnBKa1dobmdmbnZIekUxR2F5eFpiQmRicGcwTlMyUVN3Zkk4aHBFYWM0ZnZnNUg0XzZTNktyeFQ1SUw3cmx0VldjdjhGeUwzNk5FNlVFekUxb0cxdUNrUVBaS3FLc1Ixa0lIZmRqRG83VlpPdWlBVk9fN1NhZzBFMlgzWkQxN01hMkhfM094d3hWSG9nOW1BMFlJQUk2TlJjbjZiN1U2NXhEU19HdXRveDNNdGp0S08yRlUzVDZNQ1VQUHpONmNNazhtcjI?oc=5","date":"2025-03-24","type":"pipeline","source":"PR Newswire","summary":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight - PR Newswire","headline":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQRFd2RXZjNndLOGdHTkZybUwzbTg5NzduNkhOVlo5TjFmbmpRSmZtZzJXWjA5X0F5a1lqNFAxM3JYV1BfOUNJakluR3E0d0xGamF5ZlIyNWV1RmhEVUo2M054Z3haR2tCNHY5eWhJRlpRR190dVV4aFJMaldFdkxQZ0dwa2loZ0g4ZXBwT1pkdUE2REtfYl9YNW8tOXM3eEpBNGhZVHpJN2Q4cnVUMmhVOXUtVTN3ak1fNWxkcHZ3QlBjUmlWbml2RG5ENElJNjVWRERmT3pUaTNFMkwyV0JoeEo1MFVZc1hRc0xqVG85QQ?oc=5","date":"2025-03-20","type":"pipeline","source":"PR Newswire","summary":"DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight - PR Newswire","headline":"DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNcThTYnBTaFZXUXdNYzlhY0ZBdUlXNzE4cnVhSzlCVFF1T0JEeG9odldXSWtaYkQ4UmlCbzJrVVFsVWZMc0x5d1UxZkRXeUhsNTNnYkUySHNOOTZGZzVCYkNhMlBPRm1rUWpVNU9VUGhuRTlQQms4TnlpVnJEd0QyeENydmtnZkRNdmNDT0FIN3dvMVJ5SXNfS1pTTnBFWW53Y0RTazN6a2tQRXQ4ZnQwN0luYm9HTkxydE1EVVpWeS0zam9NRXp1UHlETlBkUWxYUmJIcTRvQkpyQVRLVjdIVWlqZ2U2dUtYbXVqUnhXamZVWlVSM25jT0tjX1Y0SC13dWNB?oc=5","date":"2025-03-05","type":"pipeline","source":"PR Newswire","summary":"XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight - PR Newswire","headline":"XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-27","type":"trial","source":"GlobeNewswire","summary":"Glioblastoma Market, an Area With High Trial Failure And - GlobeNewswire","headline":"Glioblastoma Market, an Area With High Trial Failure And","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQMXFyU0FSV1lhYjdpNFZvMllMdGU5eE9Mc2JVZGZtekJjajhWRkRKdzdwVzVqanFmM3FkTUt2b2gwUE1OSlMwYzBRYVQxdzBTaTV4VktDa1pWZWRCNGlfalZGYk9QcGJXaTlaQ1cwOWI0Z1RhUjR5Yl9la0NXWHlkZjVNNThjXzhLMEhNUlBZMkdGaTdrcTljeVJpSGZ1dWZwX2hkUVBqcGR0Nmk0MWZxaWhXSnMtSGVzS20xbjlISGJFSU1ocHhYdHN1WDJCdVRYOWZQSllMdHlNYldYQ2FFZUUxSHY5SDhI?oc=5","date":"2017-12-28","type":"pipeline","source":"BioSpace","summary":"Shanghai’s SARI Pays $359M for Italian Cancer Biopharma NMS - BioSpace","headline":"Shanghai’s SARI Pays $359M for Italian Cancer Biopharma NMS","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}